Temperature Controlled Packaging Market - By Type (Insulated Containers, Refrigerant Packs, Vacuum Insulated Panels, Phase Change Materials, Active Systems), By Application (Pharmaceutical, Food & Beverage, Chemicals, Electronics), By Region

The global temperature controlled packaging market size was USD 46.29 Billion in 2025 and is expected to register a revenue CAGR of 15.0% during the forecast period. Temperature controlled packaging systems maintain product temperature within defined ranges during storage, handling, and transportation through insulation, refrigerant, and active cooling or heating mechanisms. Passive systems use insulated containers combined with phase change refrigerants including water ice, dry ice, gel packs, and phase change material panels to provide temperature control for defined durations without external power. Active systems use battery-powered Peltier cooling, compressor refrigeration, or resistive heating with feedback control to maintain precise temperature setpoints independent of ambient conditions and transit duration. The pharmaceutical cold chain segment, covering vaccines, biologics, and temperature-sensitive specialty medicines, is the highest-value application, with Pelican BioThermal, Sonoco ThermoSafe, and Cryopak representing the primary passive pharmaceutical packaging suppliers. The World Health Organization reported that up to 50 percent of vaccines are wasted globally due to cold chain failures, representing a USD 34 billion annual loss that creates institutional and commercial impetus for cold chain quality improvement investment.

The temperature controlled packaging market is driven by the explosive growth of biologic drug shipments requiring 2 to 8 degrees Celsius or sub-zero storage, the expansion of direct-to-consumer pharmaceutical distribution driven by telehealth prescribing, and food safety regulatory requirements in major markets mandating temperature monitoring across the food cold chain. The global biologics market, valued at approximately USD 400 billion in 2024, requires temperature controlled packaging for 100 percent of its supply chain, making biologic drug growth a direct multiplier of cold chain packaging demand. For instance, in March 2026, Pelican BioThermal LLC, USA, announced commercial availability of its Credo ProMed 3L active temperature controlled container with 96-hour +2 to +8 degrees Celsius maintenance at ambient temperatures from minus 20 to plus 40 degrees Celsius using a battery-powered Peltier system and integrated temperature data logger, targeting pharmaceutical direct-to-patient shipment programmes replacing passive packaging in last-mile distribution. These are some of the key factors driving revenue growth of the market.

However, sustainability pressure on single-use pharmaceutical cold chain packaging is creating regulatory and procurement challenges, with the EU's Packaging and Packaging Waste Regulation requiring recyclability assessments for pharmaceutical packaging systems that currently use expanded polystyrene and multi-material composite constructions that are difficult to recycle at scale. The temperature controlled packaging market faces cost pressure from pharmaceutical logistics providers deploying reusable container systems that reduce per-shipment packaging cost by 40 to 70 percent versus single-use alternatives, gradually shifting the market from unit volume growth to system leasing revenue models. These factors substantially limit temperature controlled packaging market growth over the forecast period.